OA-43 Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01884-6

Sheeba Thomas, Elisabet Manasanch, Neha Korde, Hans Lee, Sundar Jagannath, Melody Becnel, Gregory Kaufman, Krina Patel, Swaminathan Iyer, Sham Mailankody, Donna Weber, Zuzana Lutter-Berka, Shawnee Carpenter, David Berrios Nolasco, Michelle Hildebrandt, Lei Feng, Behrang Amini, Sattva Neelapu, Robert Orlowski, Ola Landgren

引用次数: 0

查看原文本刊更多论文

伊沙妥昔单抗-来那度胺治疗高危烟雾型多发性骨髓瘤患者2期试验的OA-43中期结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.